You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)
Nonetheless, several translational challenges persist, including suboptimal homing efficiency, potential immunogenicity, and uncertain long-term safety profiles in high-altitude settings
However, the role of neuroinflammation in LTP is not straightforward, moderate levels of inflammatory mediators might facilitate LTP, while excessive inflammation typically impairs synaptic plasticity
In the folate cycle, serine donates one-carbon unit to tetrahydrofolate (THF) to form 5,10-methylene-THF (5, 10-mTHF), which fuels DNA biosynthesis and generates 5-methyl-THF (5-mTHF) (Fig
